SCHEMBL30159413

SCHEMBL30159413

NC(=O)CCCC(=O)C(N)=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 3/20 0.45
L3MBTL1 Q9Y468 1/20 0.37
CES1 P23141 6/20 0.36
CES2 O00748 5/20 0.36
BLM P54132 3/20 0.35
KMT2A Q03164 3/20 0.35
ALOX15 P16050 2/20 0.35
PMP22 Q01453 2/20 0.35
MEN1 O00255 2/20 0.35
TP53 P04637 2/20 0.35
CYP1A2 P05177 2/20 0.35
CYP3A4 P08684 2/20 0.35
CYP2C19 P33261 2/20 0.35
LDHA P00338 2/20 0.35
KDM4E B2RXH2 2/20 0.35
SLC22A6 Q4U2R8 1/20 0.35
GMNN O75496 1/20 0.35
USP2 O75604 1/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30439643 0.94 FAAH (0.50) FAAHL3MBTL1CES1CES2BLM
SCHEMBL28721888 0.87 FAAH (0.54) FAAHCES1CES2BLMKMT2A
SCHEMBL984694 0.83
SCHEMBL8921255 0.79 KMT2A (0.46) FAAHL3MBTL1BLMKMT2AALOX15
Hydrochloric Acid SCHEMBL5736439 0.79 LMNA (0.44) FAAHL3MBTL1BLMKMT2AALOX15
SCHEMBL6267121 0.79 OR51E2 (0.48) FAAHCES1CES2BLMKMT2A
SCHEMBL28907900 0.78 CES2 (0.55) FAAHCES1CES2KMT2AALOX15
SCHEMBL5067376 0.77
SCHEMBL8725568 0.77
SCHEMBL11517057 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240383856-A1 INHIBITORS OF TRANSGLUTAMINASES ZEDIRA GMBH (DE) 2024-11-21 US claimed
US-20240376055-A1 INHIBITORS OF TRANSGLUTAMINASES ZEDIRA GMBH (DE) 2024-11-14 US claimed
US-20240270715-A1 INHIBITORS OF TRANSGLUTAMINASES ZEDIRA GMBH (DE) 2024-08-15 US claimed
EP-4192813-B1 INHIBITORS OF TRANSGLUTAMINASES ZEDIRA GMBH (DE) 2024-08-14 EP claimed
EP-4192814-B1 INHIBITORS OF TRANSGLUTAMINASES ZEDIRA GMBH (DE) 2024-08-07 EP claimed
EP-3405477-B1 INHIBITORS OF TRANSGLUTAMINASES ZEDIRA GMBH (DE) 2023-06-07 EP claimed
US-20240383856-A1 INHIBITORS OF TRANSGLUTAMINASES ZEDIRA GMBH (DE) 2024-11-21 US disclosed
US-20240376055-A1 INHIBITORS OF TRANSGLUTAMINASES ZEDIRA GMBH (DE) 2024-11-14 US disclosed
US-20240270715-A1 INHIBITORS OF TRANSGLUTAMINASES ZEDIRA GMBH (DE) 2024-08-15 US disclosed
EP-4192813-B1 INHIBITORS OF TRANSGLUTAMINASES ZEDIRA GMBH (DE) 2024-08-14 EP disclosed
WO-2023110138-A1 INHIBITORS OF TRANSGLUTAMINASES ZEDIRA GMBH (DE) 2023-06-22 WO disclosed
EP-4192814-A1 INHIBITORS OF TRANSGLUTAMINASES Zedira GmbH (DE) 2023-06-14 EP disclosed
WO-2023275337-A1 INHIBITORS OF TRANSGLUTAMINASES ZEDIRA GMBH (DE) 2023-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240383856-A1 INHIBITORS OF TRANSGLUTAMINASES TGM2, TGM3, TGM1 FAAH 1123/4885L3MBTL1 3414/4885CES1 178/4885
US-20240376055-A1 INHIBITORS OF TRANSGLUTAMINASES TGM2, TGM3, TGM1 FAAH 1123/4885L3MBTL1 3414/4885CES1 178/4885
US-20240270715-A1 INHIBITORS OF TRANSGLUTAMINASES TGM2, TGM3, TGM1 FAAH 1123/4885L3MBTL1 3414/4885CES1 178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.